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ABSTRACT 
The present study is focused on the development of gastroretentive floating drug delivery system of ambroxol hydrochloride, which acts as a 
mucolytic agent that is reported to be useful in gastric neoplasms which are designed to increase the gastric residence time,  thus prolonging the 
drug release in the stomach. Gastro retentive floating tablets of ambroxol hydrochloride were prepared by direct compression method using 
altered concentrations of HPMC K4, HPMC K15 and PVP K30 as polymers. Sodium bicarbonate and citric acid was used as gas releasing agent. 
The prepared tablets of ambroxol hydrochloride were evaluated for hardness, thickness, friability, weight variation, drug content uniformity, 
buoyancy lag time, total floating time, in-vitro dissolution study, etc. All the compositions were resulted in adequate Pharmacopoeial limits. 
Compatibility studies was execution during FTIR shown that there was absence of probable chemical interaction between pure drug and 
excipients. The varying concentration of gas generating agent and polymers was found to affect on in-vitro drug release and floating lag time. In 
vitro drug release of floating gastro retentive tablet of ambroxol hydrochloride shown that the formulation F6 was found to be the best 
formulation as it releases 99.87% in a controlled manner for an extended period of time (up to 12 hrs). The release data was fitted to various 
mathematical models such as Higuchi, Korsmeyer-Peppas, First order and Zero order to evaluate the kinetics and mechanism of the drug 
release. The optimized formulation (F6) showed no significant change in physical parameters such as, hardness, friability, weight variation and 
%drug content for accelerated stability condition at 40±2oC temperature and 75±5% relative humidity for a period 3 months.   Prepared 
floating tablets of ambroxol hydrochloride may prove to be a potential candidate for safe and effective controlled drug delivery over an 
extended period of time for gastro retentive drug delivery system. 
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The oral bioavailability of many drugs is limited by their 
unfavourable physicochemical characteristics or absorption 
in well-defined part of the gastrointestinal tract (GIT) 
referred as absorption window1. Prolonged gastric retention 
improves bioavailability, reduces drug waste and improves 
the solubility for drugs that are less soluble in a high pH 
environment2. Various approaches have been investigated to 
increase the retention of oral dosage form in the stomach, 
including floating systems, swelling, expanding systems, 
bioadhesive systems, modified shape systems, high density 
systems and other delayed gastric emptying devices1. 
Ambroxol hydrochloride is a metabolite of bromhexine and 
is official in the Martindale Extra pharmacopoeia3. It is 
chemically described as Trans-4-[(2-Amino-3, 5-dibromo 
benzyl) amino]-cyclohexanol. It is widely used as an 
expectorant and a mucolytic agent used in the treatment of 
respiratory disorders such as chronic bronchitis and 
bronchial asthma. Ambroxol hydrochloride is capable of 
inducing thin copious bronchial secretion4. It depolymerizes 
mucopolysaccharides directly as well as by liberating 
lysosomal enzymes network of fibers in tenacious sputum is 
broken5. Ambroxol hydrochloride is sparingly water 
solubility. Hence, it presents significant formulation 
challenges. Ambroxol hydrochloride has a half-life of 4 h and 
the usual oral dosage regimen is 75 mg6. Hydroxy propyl 
methyl cellulose (HPMC) is hydrophilic cellulose ether 
widely used as release retarding material. HPMC releases 
drug by diffusion mechanism7. The objective of the present 
study was to develop a gastroretentive floating drug delivery 
system (GFDDS) of ambroxol hydrochloride and to examine 
the effects of various polymers on in vitro drug release will 
provide once daily, sustained release dosage form of 
ambroxol hydrochloride.  
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MATERIALS AND METHODS 
Materials  
Ambroxol hydrochloride was received as gift sample from 
Trojan Pharma, Baddi, India. Hydroxypropyl methylcellulose 
(HPMC K4M, HPMC K15M) was procured from Meditab 
Specialities Pvt. Ltd., Satara. PVP K30 was purchased from 
S.D fine chemicals, Mumbai. Sodium bicarbonate, citric acid, 
magnesium stearate, talc were purchased from Mapromax, 
Life sciences Pvt. Ltd., Dehradun. Other solvents and 
chemicals used in the research were of LR grade. All the 
studies were carried in distilled water. 
Methods 
Preformulation studies 
Determination of λ max of Ambroxol hydrochloride  
Accurately weighed 10 mg of drug was dissolved in 10 ml of 
0.1N HCl solutions in 10 ml of volumetric flask. The resulted 
solution 1000µg/ml and from this solution 1 ml pipette out 
and transfer into 10 ml volumetric flask and volume make up 
with 0.1N HCl solution. Prepare suitable dilution to make it 
to a concentration range of 5-25μg/ml. The spectrum of this 
solution was run in 200-400 nm range in U.V. 
spectrophotometer (Labindia-3000+).  
Fourier Transform Infrared (FTIR) spectroscopy 
The physical properties of the physical assortment were 
comparing with those of ambroxol hydrochloride pure drug. 
Samples was assorted comprehensively through 100mg 
potassium bromide IR powder as well as compacted under 
vacuum at a pressure of concerning 12 psi for 3 minutes. The 
ensuing disc was mounted in an appropriate holder in 
Brukers Alpha IR spectrophotometer and the IR spectrum 
was recorded from 3500 cm to 500 cm. The resultant 
spectrum was compared for any spectrum changes. 
Formulation development of Tablets 
Direct compression method 
Different tablets formulations (F1-F7) were prepared by 
direct compression technique. All powders were passed 
through 40 meshes. Required quantities of drug and 
polymers were mixed thoroughly, Magnesium stearate was 
added as lubricant. Talc was used as glidant and sodium 
bicarbonate and citric acid were used as gas generating 
agent. Finally the powder mix was subjected to compression 
after mixing uniformly in a polybag. Prior to compression, 
the blends were evaluated for several tests8. The 
composition of ambroxol hydrochloride floating tablets was 
shown in Table 1. 
  
Table 1 Formulation composition of sustained release gastro-retentive floating tablets of ambroxol hydrochloride 
Excipients F1 F2 F3 F4 F5 F6 F7 
Ambroxol HCl 75 75 75 75 75 75 75 
HPMCK 15 25 50 75 100 125 150 - 
HPMC K 4 125 100 75 50 25 - 150 
PVP K30 15 15 15 15 15 15 15 
Citric acid 25 25 25 25 25 25 25 
Sodium bicarbonate 50 50 50 50 50 50 50 
Magnesium stearate 10 10 10 10 10 10 10 
Talc 5 5 5 5 5 5 5 
 
 
Evaluation of tablets 
All the tablets were evaluated for following different 
parameters which includes; 
General Appearance 
Five tablets from various batches were randomly selected 
and organoleptic properties such as color, odor, taste, shape 
were evaluated. Appearance was judged visually. Very good 
(+++), good (++), fair (+) poor (-), very poor (- -). 
Thickness and diameter 
Thickness and diameter of tablets were determined using 
Vernier caliper. Five tablets from each batch were used and 
an average value was calculated. 
Hardness 
For each formulation, the hardness of five tablets was 
determined using the Monsanto hardness tester (Cadmach). 
Friability 
The friability of a sample of 10 tablets was measured using a 
Friability tester (Electro Lab).Ten tablets were weighed, 
rotated at 25 rpm for 4 minutes. Tablets were reweighed 
after removal of fines (dedusted) and the percentage of 
weight loss was calculated. 
Uniformity of weight 
Twenty tablets were randomly selected from each batch 
individually weighed, the average weight and standard 
deviation of 20 tablets was calculated. 
Drug content 
Twenty tablets were taken and amount of drug present in 
each tablet was determined. The tablets were crushed in a 
mortar and the powder equivalent to 100mg of drug was 
transferred to 100ml standard flask. The powder was 
dissolved in 50 ml of 0.1 N HCl and made up to volume with 
of 0.1 N HCl. The sample was mixed thoroughly and filtered 
through a 0.45μ membrane filter. The filtered solution was 
diluted suitably and analyzed for drug content by UV 
spectrophotometer at a λmax of 244 nm using of 0.1 N HCl as 
blank. 
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In vitro buoyancy studies 
In vitro buoyancy was determined by floating lag time as per 
the method described by Rosa et al9. The tablets were 
separately in a 100 ml glass beaker containing simulated 
gastric fluid (SGF), pH 1.2 as per USP. The time necessary for 
the tablet to increase to the outside and float was determined 
as floating lag time. The experiments were conducted in 
triplicate. Total floating times were measured during in 
vitro dissolution studies. 
Dissolution rate studies 
In vitro drug release of the sample was done using USP-type 
II dissolution apparatus (Paddle type). The dissolution 
medium, 900 ml 0.1N HCl was set into the dissolution flask 
maintaining the temperature of 37±0.50c and rpm of 75. One 
ambroxol hydrochloride tablet was set in every container of 
dissolution apparatus. The mechanical assembly was 
permitted to keep running for 10 hours. Sample measuring 5 
ml were pulled back after each 1 hour up to 10 hours using 
10ml pipette. The new disintegration medium (370C) was 
supplanted each time with a similar amount of the sample 
and takes the absorbance at 244nm using spectroscopy10-12. 
Mathematical treatment of in-vitro release data 
 The quantitative analysis of the qualities got in 
dissolution/release tests is simpler when mathematical 
formulas that express the dissolution comes about as an 
element of a portion of the measurement frames attributes 
are utilized. 
Zero-order kinetics 
 The pharmaceutical dosage frames following this profile 
release a similar measure of medication by unit of time and it 
is the ideal method of medication release keeping in mind 
the end goal to accomplish a pharmacological prolonged 
action. The following relation can, in a simple way, express 
this model: 
Qt = Qo + Ko t 
Where Qt is the amount of drug dissolved in time t, Qo is the 
initial amount of drug in the solution (most times, Qo=0) and 
Ko is the zero order release constant. 
First-order kinetics 
 The following relation expresses this model: 
 
Where Qt is the amount of drug dissolved in time t, Qo is the 
initial amount of drug in the solution and K1 is the zero order 
release constant. 
Along these lines a graphic of the decimal logarithm of the 
released measure of drug versus time will be linear. The 
pharmaceutical dosage shapes following this dissolution 
profile, for example, those containing water-solvent drugs in 
permeable frameworks, discharge drug in a way that is 
corresponding to the measure of drug staying in its inside, in 
such way, that the measure of drug released by unit of time 
reduce. 
Higuchi model 
Higuchi built up a few theoretical models to ponder the 
arrival of water-solvent and low dissolvable medications in 
semi-strong or potentially strong grids. Mathematical 
expressions were acquired for sedate particles scattered in a 
uniform grid acting as the diffusion media. The simplified 
Higuchi model is expressed as: 
 
Where Q is the amount of drug released in time t and KH is 
the Higuchi dissolution constant. Higuchi model describes 
drug release as a diffusion process based in the Fick’s law, 
square root time dependent. This relation can be utilized to 
portray the drug dissolution from a few kinds of modified 
release pharmaceutical dosage structures, for example, 
transdermal systems and matrix tablets with water-
dissolvable drugs. 
Korsmeyer-Peppas model 
 Korsmeyer et al. used a simple empirical equation to 
describe general solute release behaviour from controlled 
release polymer matrices:  
 
Where Mt/M is fraction of drug released, is kinetic constant, 
t is release time and n is the diffusional exponent for drug 
release. ’n’ is the slope value of log Mt/M  versus log time 
curve. Peppas stated that the above equation could 
adequately describe the release of solutes from slabs, 
spheres, cylinders and discs, regardless of the release 
mechanism. Peppas used this n value in order to characterize 
different release mechanisms, concluding for values for a 
slab, of n =0.5 for fickian diffusion and higher values of n, 
between 0.5 and 1.0, or n =1.0, for mass transfer following a 
non-fickian model. In case of a cylinder n =0.45 instead of 
0.5, and 0.89 instead of 1.0. This equation can only be used in 
systems with a drug diffusion coefficient fairly concentration 
independent. To the determination of the exponent n the 
portion of the release curve where Mt/M  < 0.6 should only 
be used. To use this equation it is also necessary that release 
occurs in a one-dimensional way and that the system width-
thickness or length-thickness relation be at least 10. A 
modified form of this equation was developed to 
accommodate the lag time (l) in the beginning of the drug 
release from the pharmaceutical dosage form: 
 
When there is the possibility of a burst effect, b, this equation 
becomes: 
 
In the absence of lag time or burst effect, l and b value would 
be zero and only atn is used. This mathematical model, also 
known as Power Law, has been used very frequently to 
describe release from several different pharmaceutical 
modified release dosage forms13-15. 
Stability studies  
The optimized formulation of ambroxol hydrochloride were 
packed in strips of 0.04 mm thick aluminum foil laminated 
with poly vinyl chloride by strip packing and these packed 
formulations were stored in ICH certified stability chambers 
(Thermo labs, Mumbai) maintained at 400C and 75% RH for 
3 months. The samples were withdrawn at 1, 2 and 3 months 
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interval and evaluated for physical parameters such as, 
hardness, friability, weight variation and %drug content. 
RESULTS AND DISCUSSION 
The λmax of ambroxol hydrochloride was found to be 244 nm 
by using UV spectrophotometer (Labindia-3000+) in 
linearity range 5-25µg/ml Fig.1. Identification of ambroxol 
hydrochloride was done by FTIR spectroscopy with respect 
to marker compound. It was identified from the result of IR 
spectrum as per specification. Ambroxol hydrochloride 
tablet quality control tests such as weight variation, hardness 
and friability, thickness, drug content and drug release 
studies in 0.1 N HCl were performed on the compression 
tablet. All the parameters such as weight variation, hardness, 
friability, thickness and drug content were found to be within 
limits Table 2.  
 
Fig. 1 Determination of λmax of ambroxol hydrochloride
 
Table 2 Results of post compression properties of ambroxol hydrochloride GRF tablets 










F1 3.53±0.05 4.8 328.19± 2.94 0.58 ± 0.10 98.33± 0.92 8 
F2 3.94± 0.10 4.4 332.18 ± 3.77 0.51 ± 0.08 97.20 ± 0.34 10 
F3 3.96± 0.05 4.5 335.33 ± 1.50 0.38 ± 0.12 99.60 ± 1.39 >12 
F4 3.95± 0.05 4.7 336.30 ± 3.30 0.16 ± 0.04 98.14 ± 1.69 >12 
F5 3.93± 0.10 5.2 327.13 ± 2.83 0.31 ± 0.07 97.21 ± 1.07 >12 
F6 4.03± 0.06 5.3 332.16 ± 2.33 0.27 ± 0.05 97.50± 1.81 >12 
F7 4.05± 0.05 4.8 338.18 ± 3.11 0.29 ± 0.08 98.34 ± 0.37 >12 
 
In the present study 7 formulations with variable 
concentration of polymers (HPMC K4, K 15) were prepared 
by direct compression method and evaluated for 
physicochemical properties. The results of buoyancy lag 
time, total floating time and in vitro drug release was given in 
Table 3, 4. The results indicated that optimizes formulation 
F6 on immersion in 0.1N HCl at 37±0.50C tablets immediately 
and remain buoyant up to 12hr without disintegration. These 
2 factors are essential for tablets to acquire density< 1, so 
that it remains buoyant on the gastric fluids. The in vitro 
drug release data of the optimized formulation was subjected 
to goodness of fit test by linear regression analysis according 
to zero order, first order kinetic equation, higuchi’s and 
korsmeyer’s models in order to determine the mechanism of 
drug release. When the regression coefficient values of were 
compared, it was observed that ‘r’ values of first order was 
maximum i.e. 0.981hence indicating drug release from 
formulations was found to follow first order release kinetics. 
Table 5 & Fig. 2-5. After storage of sustained release gastro-
retentive floating tablets of ambroxol hydrochloride (F6) 
were analyzed for various physical parameters, results are 
showed in table. 6. Therefore formulation remains stable for 
sufficient time. 
 
Table 3 Results of in-vitro buoyancy study of ambroxol HCl 
Formulation code Buoyancy lag times (sec) Total floating time (hrs) 
F1 25s >8 
F2 35s >10 
F3 56s >12 
F4 75s >12 
F5 60s >12 
F6 80s >12 
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Table 4 In-vitro drug release study of GRF tablets 
Time % of Drug Release 
(hr) F1 F2 F3 F4 F5 F6 F7 
0.5 08.23 07.14 07.24 08.23 07.23 07.45 08.32 
1 12.32 10.23 11.45 10.45 10.45 11.23 12.23 
1.5 26.23 22.42 24.23 23.76 31.23 38.23 32.13 
2 42.45 40.32 45.23 44.23 48.23 46.32 47.14 
3 76.34 66.11 67.21 65.71 50.56 67.02 71.13 
4 82.23 77.33 75.11 82.34 55.00 88.13 91.23 
6 82.55 97.13 87.13 83.00 56.00 99.13 92.00 
8 83.00 97.10 94.23 83.21 57.25 99.99 93.00 
12 84.21 97.23 99.26 83.50 57.85 99.87 94.56 
 
Table 5 Regression analysis data of ambroxol HCl floating tablets 
Batch 
Zero Order First Order Higuchi Korsmeyer-Peppas 
R² R² R² R² 
F6 0.675 0.981 0.896 0.896 
 
 
Fig. 2 Zero order release Kinetics  
 
Fig. 3 First order release kinetics  
 
Fig. 4 Higuchi release Kinetics  
 
Fig. 5 Korsmeyer-Peppas release Kinetics
 




After  1 month 
storage 
After 2 months 
Storage 
After 3 months 
storage 
Hardness (kg/cm2) 5.2±0 5.2±0 5.2±0 5.2±0 
Friability (%) 0.31 0.33 0.34 0.34 
Drug content (%) 98.3±0.49 97.84±0.3 97.45±0.37 97±0.03 
Weight variation 
(mg) 
327.13±2.8 327.37±0.39 328.09±0.75 328.03±0.45 
 
 
y = 11.254x 
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CONCLUSION  
Ambroxol HCl floating tablets were successfully formulated 
by floating technique. The optimized formulation (F6) was 
selected on the basis of in vitro buoyancy and in vitro drug 
release. The addition of gel forming agent and gas generating 
agent was essential to achieve in vitro buoyancy. The results 
of the in vitro drug release and in vitro buoyancy study 
showed that the optimized formulation (F6) sustained the 
drug release (99.87) up to 12 hrs and remained buoyant for 
>12 hrs. Optimized formulation (F6) does not show any 
significant change in physical parameters such as hardness, 
friability, weight variation and %drug content after storage 
at 40°C/75% RH and stable for 3 months. 
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